Page last updated: 2024-12-11

1-[2-(4-methoxyphenyl)ethyl]-3,5-dimethyl-4-nitropyrazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-[2-(4-methoxyphenyl)ethyl]-3,5-dimethyl-4-nitropyrazole, also known as **DMNP**, is a **pyrazole derivative** with potential applications in **drug discovery and chemical biology**.

**Structure and Properties:**

* DMNP consists of a pyrazole ring with two methyl groups at positions 3 and 5, a nitro group at position 4, and a 4-methoxyphenethyl substituent at position 1.
* It is a **solid compound** with a specific melting point.

**Importance in Research:**

DMNP is an interesting molecule for research due to several reasons:

1. **Potent PPARα Agonist:** PPARα (Peroxisome Proliferator-Activated Receptor alpha) is a nuclear receptor involved in regulating lipid metabolism, inflammation, and glucose homeostasis. DMNP has shown **potent agonist activity for PPARα**. This means it can activate the receptor, potentially leading to beneficial effects on lipid levels, inflammation, and metabolic diseases.
2. **Anti-Inflammatory Properties:** DMNP has demonstrated **anti-inflammatory properties** in various experimental models. Its ability to activate PPARα contributes to its anti-inflammatory effects.
3. **Potential Therapeutic Applications:** The combination of its potent PPARα agonist activity and anti-inflammatory properties makes DMNP a promising candidate for developing **new therapies for metabolic disorders**, such as type 2 diabetes and hyperlipidemia, as well as inflammatory conditions.
4. **Chemical Biology Tool:** DMNP can be used as a **chemical probe** to study the role of PPARα in cellular processes and to identify novel PPARα ligands with improved pharmacological properties.

**Current Research:**

* Research is ongoing to investigate the **efficacy and safety** of DMNP in preclinical models.
* Scientists are exploring the **mechanism of action** of DMNP and its interactions with PPARα.
* Efforts are underway to **optimize the structure of DMNP** to improve its potency, selectivity, and pharmacokinetic properties.

**Overall, 1-[2-(4-methoxyphenyl)ethyl]-3,5-dimethyl-4-nitropyrazole (DMNP) is a promising compound with potential applications in drug discovery and chemical biology due to its potent PPARα agonist activity, anti-inflammatory properties, and ability to serve as a chemical probe. Further research is needed to fully assess its therapeutic potential.**

Cross-References

ID SourceID
PubMed CID8487428
CHEMBL ID1547367
CHEBI ID121869

Synonyms (9)

Synonym
MLS001151246
smr000688582
CHEBI:121869
AKOS017091640
1-[2-(4-methoxyphenyl)ethyl]-3,5-dimethyl-4-nitropyrazole
HMS2982J19
CHEMBL1547367
Q27210470
Z54488279
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methoxybenzenesAny aromatic ether that consists of a benzene skeleton substituted with one or more methoxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency11.99550.007215.758889.3584AID588342
BRCA1Homo sapiens (human)Potency8.91250.89137.722525.1189AID624202
ATAD5 protein, partialHomo sapiens (human)Potency18.47060.004110.890331.5287AID504466; AID504467
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency3.16230.01262.451825.0177AID485313
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency25.92900.00419.984825.9290AID504444
ras-related protein Rab-9AHomo sapiens (human)Potency3.16230.00022.621531.4954AID485297
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency44.66840.425612.059128.1838AID504891
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]